We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 12, 2021

Rivaroxaban vs Placebo in High-Risk Adults With Mild COVID

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

 

Additional Info

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19
Clin. Infect. Dis. 2021 Sep 15;[EPub Ahead of Print], J Ananworanich, R Mogg, MW Dunne, M Bassyouni, CV David, E Gonzalez, T Rogalski-Salter, H Shih, J Silverman, J Medema, P Heaton

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading